Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice

Radium-223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases (ALSYMPCA trial). Our aim was to assess clinical and biochemical factors related to survival, safety and survival o...

Descripción completa

Detalles Bibliográficos
Autores principales: Prelaj, Arsela, Rebuzzi, Sara Elena, Buzzacchino, Federica, Pozzi, Chiara, Ferrara, Carla, Frantellizzi, Viviana, Follacchio, Giulia Anna, Civitelli, Liana, De Vincentis, Giuseppe, Tomao, Silverio, Bianco, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341517/
https://www.ncbi.nlm.nih.gov/pubmed/30675201
http://dx.doi.org/10.3892/ol.2018.9785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341517/
https://www.ncbi.nlm.nih.gov/pubmed/30675201
http://dx.doi.org/10.3892/ol.2018.9785

Ejemplares similares